Evidence map›Paper›PMID 28292726›Full record

ReviewBiomaterials2017

Cell membrane-derived nanomaterials for biomedical applications.

Ronnie H Fang, Yao Jiang, Jean C Fang, Liangfang Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomaterials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers.

0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

162 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Engineering Bacteria as Living Therapeutics in Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  18. Review
  19. Review
  20. Article

102 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ronnie H FangDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Yao JiangDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Jean C FangDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Liangfang ZhangDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: zhang@ucsd.edu.

Funding

Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma MetastasisR01CA200574 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LI, SHULIN, ZHANG, LIANGFANG · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA200574
6 · The paper itself

Abstract

The continued evolution of biomedical nanotechnology has enabled clinicians to better detect, prevent, manage, and treat human disease. In order to further push the limits of nanoparticle performance and functionality, there has recently been a paradigm shift towards biomimetic design strategies. By taking inspiration from nature, the goal is to create next-generation nanoparticle platforms that can more effectively navigate and interact with the incredibly complex biological systems that exist within the body. Of great interest are cellular membranes, which play essential roles in biointerfacing, self-identification, signal transduction, and compartmentalization. In this review, we explore the major ways in which researchers have directly leveraged cell membrane-derived biomaterials for the fabrication of novel nanotherapeutics and nanodiagnostics. Such emerging technologies have the potential to significantly advance the field of nanomedicine, helping to improve upon traditional modalities while also enabling novel applications.

Indexed as

AnimalsBiomedical TechnologyBiosensing TechniquesCell MembraneDrug Delivery SystemsHumansImmunomodulationNanostructuresBiomimetic nanoparticleCell membraneDetoxificationDrug deliveryImagingImmunotherapy

Identifiers

PMID28292726
PMCPMC5417338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.